TONE NOTES · A MELASMA READING GUIDERESEARCHED OCTOBER 2026
tone●notes
Advertising disclosure: CoreAge Rx is our featured commercial partner and appears first. Placement is promotional; it is not a clinical superiority ranking. How we are funded
The reading list

Hydroquinone: the questions supervision should answer

The ingredient, formulation and treatment window belong in the same conversation.

Use the right product and source

FDA warns about unapproved over-the-counter skin-lightening products containing hydroquinone and about products contaminated with mercury. A familiar ingredient name on an online listing does not establish a legitimate or appropriate medicine.[source]

For a prescribed product, identify the dispensing source and read the actual label. A custom preparation and a fixed approved drug should remain separate categories even when both include hydroquinone.

Ask what will be reviewed and when

The useful questions concern the diagnosed condition, proposed concentration, application area, expected review point and what to do if irritation or an unusual color change develops. Those decisions cannot be inferred from another person’s refill schedule.

A corticosteroid or retinoid in a combination introduces additional considerations. The TRI-LUMA label, for example, has explicit short-term and maintenance limitations, so its use should not be extended casually.[source]

Do not turn strength into a competition

Higher advertised concentrations do not automatically produce a better balance of effect and tolerability. The overall formulation, skin history and supervision matter. Agency also notes that some Dark Spot Rx formulas do not contain hydroquinone at all.[source]

If the main uncertainty is whether hydroquinone fits the person’s situation, ask that before comparing subscription discounts. A review can organize the evidence and questions, but it cannot determine the appropriate concentration or length of treatment.

THE RESEARCH

Sources & further reading

Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.

  1. FDA: warnings about skin-lightening productsOfficial source; checked October 8, 2026 · Checked October 8, 2026
  2. DailyMed: current TRI-LUMA prescribing informationGalderma drug labeling; current accessible version checked October 8, 2026 · Checked October 8, 2026
  3. Agency: Dark Spot RxOfficial source; checked October 8, 2026 · Checked October 8, 2026

Keep reading